Our cost-method investments are included in “Investments” in the condensed consolidated balance sheets and consist of our equity positions in the following privately-held companies (in thousands):



	June 30, 2018		December 31, 2017
Respicardia Inc. ⁽¹⁾	$	17,705	$	17,422
ImThera Medical, Inc. ⁽²⁾	—		12,900
Rainbow Medical Ltd. ⁽³⁾	1,140		1,172
MD Start II ⁽⁴⁾	1,164		1,199
Highlife S.A.S. ⁽⁵⁾	1,104		—
Other	17		17
	$	21,130	$	32,710

(1)

Respicardia Inc. (“Respicardia”) is a privately funded U.S. company developing an implantable device designed to restore a more natural breathing pattern during sleep in patients with central sleep apnea ("CSA") by transvenously stimulating the phrenic nerve. We have a loan outstanding to Respicardia with a carrying amount of $0.5 million, as of June 30, 2018, which is included in “Prepaid expenses and other current assets” in the condensed consolidated balance sheet.


(2)	On January 16, 2018, we acquired the remaining outstanding interests in ImThera. Refer to “Note 3. Business Combinations”.


(3)	Rainbow Medical Ltd. is a private Israeli venture capital company that seeds and grows companies developing medical devices in a diverse range of medical fields.


(4)	MD Start II is a private venture capital collaboration for the development of medical device technology in Europe.

(5)

Due to an additional investment by a third party during the three months ended June 30, 2018, our equity interest in Highlife S.A.S. (“Highlife”) decreased to 17.5% from 24.6%. We determined that we no longer had significant influence over Highlife and it is now considered a cost method investment. The carrying amount of our equity-method investment in Highlife was $1.8 million at December 31, 2017.